GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 1.637 M

Revenue: As of FY2025 Q1, the actual value is USD 1.637 M.

EPS: As of FY2025 Q1, the actual value is USD -0.45.

Net Loss

Net loss for the three months ended March 31, 2025, was $5.4 million, compared to $5.9 million for the same period in 2024.

Revenue

For the three months ended March 31, 2025, GeoVax reported $1.6 million in government contract revenues associated with the BARDA/RRPV Project NextGen award, whereas no revenues were reported during the comparable 2024 period.

Research and Development Expenses

Research and development expenses were $5.4 million for the three months ended March 31, 2025, compared to $4.4 million for the same period in 2024, primarily due to costs associated with the BARDA/RRPV Project NextGen award and the Gedeptin and GEO-MVA programs.

General and Administrative Expenses

General and administrative expenses were $1.7 million for the three months ended March 31, 2025, compared to $1.5 million for the same period in 2024, with the increase primarily due to higher investor relations consulting costs and stock-based compensation expense.

Cash Position

GeoVax reported cash balances of $7.4 million at March 31, 2025, compared to $5.5 million at December 31, 2024.

Outlook / Guidance

GeoVax anticipates key data readouts for its GEO-CM04S1 COVID-19 vaccine program in the first half of 2025, with clinical trials for GEO-MVA expected to initiate in the second half of 2025. The company is advancing its Gedeptin technology into Phase 2 trials for head and neck cancer, reflecting a strategic focus on innovative immunotherapies and vaccines.